论文部分内容阅读
在国家科技部863计划课题及欧盟第五框架INCO项目的资助下,中国疾病预防控制中心与北京生物制品研究所联合研制的DNA -天坛痘苗复合型艾滋病疫苗于日前在北京协和医院开始Ⅰ期临床试验的招募工作,并开始第一组志愿者的疫苗接种。该艾滋病疫苗包括DNA疫苗及复制型重组痘苗病毒疫苗两个组分,具有我国自主知识产权。疫苗的免疫原选自在我国流行最广的HIM毒株CRF-07,包括gag,pol.env和nef四个基因。疫苗的载体选用天坛株痘苗病毒,该痘苗病毒曾广泛应用于我国的天花疫苗。该疫苗载
With the support of the Ministry of Science and Technology 863 Program and the EU's fifth framework INCO project, the DNA-Tiantan vaccinia composite AIDS vaccine jointly developed by the China Center for Disease Control and Prevention and Beijing Institute of Biological Products recently started Phase I clinical trial at Peking Union Medical College Hospital Trials were recruited to work and vaccinations were started for the first group of volunteers. The AIDS vaccine includes DNA vaccine and recombinant vaccinia virus vaccine two components, with China's independent intellectual property rights. The immunogen of the vaccine is selected from the HIM strain CRF-07 which is the most prevalent in our country, including the four genes gag, pol.env and nef. Vaccine carrier selection Temple of Heaven strains of vaccinia virus, the vaccinia virus has been widely used in our smallpox vaccine. The vaccine contains